FDA Poised to Review Peptide Substances Amid Safety Concerns

Health advisers are meeting to examine over half a dozen peptides, substances gaining popularity in wellness trends, despite insufficient evidence of their safety or effectiveness. This meeting, conducted by the Food and Drug Administration (FDA), is supported by Health Secretary Robert F. Kennedy Jr., who advocates for peptides and opposes restrictions established under President Joe Biden.

Prominent figures like podcaster Joe Rogan and wellness influencer Gary Brecka endorse peptides. Brecka, connected to Kennedy’s health agenda, sells peptide vials online. Social media is replete with claims that peptides help in muscle building, injury recovery, or achieving a youthful appearance.

However, the FDA meeting is expected to reveal a division over these compounds. FDA scientists doubt there’s sufficient data to promote broader availability of peptides, especially through compounding pharmacies that create personalized medicines not offered by traditional drug manufacturers.

“This is really alarming,” said Rita Jew, president of the Institute for Safe Medication Practices. “There aren’t that many other substances people are injecting into themselves where you see that the clinical evidence is so lacking.”

Concerns arise due to the advisory panel having members with financial ties to the peptide industry, including wellness clinic owners, pharmacy operators, and online consultants. Previous expert panels appointed by Kennedy faced scrutiny over apparent conflicts of interest.

Recently, the FDA added more academics without industry connections to the advisory panel, aiming for a balanced discussion. FDA scientists remain skeptical about peptide safety and benefits, voting on whether seven peptides should be approved for pharmacy compounding.

Peptides, essential for body growth, metabolism, and healing, have been developed by drug companies for diabetes and weight loss treatments. Supporters urge the FDA to consider peptides for conditions like ulcerative colitis, migraines, and opioid addiction.

Recent FDA warnings highlighted risks of injecting peptides such as BPC-157 and TB-500, both set for assessment. Promoted online for injury recovery and inflammation reduction, these chemicals are classified as doping substances in sports. FDA reviews express ongoing concerns over safety, contamination, allergic reactions, and effectiveness, with limited data mostly from animal studies rather than humans.

The FDA’s assessment spans more than 18 hours of discussions and presentations over two days, offering public participation chances. Ahead of the meeting, over 1,900 public comments were received, including support from doctors and patients citing peptide benefits.

The American Academy of Peptide Medicine argues for safe, legal access to peptides from regulated pharmacies, emphasizing its educational role over licensing or accreditation.

Post-meeting, the FDA will review votes, discussions, and public input before deciding on peptide access. Observers anticipate a temporary policy mitigating enforcement against pharmacies compounding peptides under review. Officially listing substances for compounding demands new regulations, a process that may extend over months or years.

“We’re still going through this process, but I think it’s more than likely that the process will end up at the result that Secretary Kennedy wants,” said Nathan Beaver, an attorney specializing in FDA issues.

—
The Associated Press Health and Science Department receives backing from Howard Hughes Medical Institute’s Department of Science Education and the Robert Wood Johnson Foundation, with editorial content responsibility solely held by the AP.